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A B S T R A C T
In this article, we discuss certain contemporary and controversial topics in cardiovascular (CV) nutrition
including recent data regarding the health beneﬁts of the Mediterranean diet, the role of saturated fatty
acids, red meat and the microbiome in CV disease and the current role of personalized CV nutrition.
Findings from the PREDIMED study now demonstrate the health beneﬁts of the Mediterranean diet even
in the absence of heart disease. The study highlighted that even small, sustained and easily
implementable changes to diet can provide signiﬁcant health beneﬁts even in Mediterranean regions.
Likewise, observational data in secondary prevention show that increased adherence to the
Mediterranean diet is associated with good long-term clinical outcomes among subjects with stable
coronary heart disease. The role of saturated fats in the development of CV disease remains controversial,
although data suggest that these fats are associated with modestly increased risk of CV events. In
contrast, the obesity epidemic currently driving the CV risk worldwide is in large part due to excess
consumption of reﬁned carbohydrates. Furthermore, a growing body of evidence suggests that the
intestinal microbiome is highly sensitive to lifestyle choices and may play a pivotal role in modulating CV
disease development. For example, recent evidence linking processed and unprocessed meats to
increased CV risk pointed to the gut microbial metabolite trimethylamine N-oxide as a potential culprit.
Finally, given the high interindividual variability in response to interventions including diet,
personalized nutrition has potential to play a major role in tailoring diets based on genetic make-up
to maximize health beneﬁts. This approach is still in its infancy but is highly promising.
 2016 Published by Elsevier Masson SAS.
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Cardiovascular (CV) nutrition remains a cornerstone of a
complete cardiac rehabilitation program. According to the most
recent data from the World Health Organization, hypertension,
high blood sugar, excess weight and hypercholesterolemia
represent 4 of the 10 greatest risk factors for all-cause mortality
worldwide [1]. These risk factors highlight the vital role that
nutrition plays in health and disease. The same can be said at the
individual level. The contemporary patient with CV disease (CVD)
not only has underlying heart disease but most often has multiple* Corresponding author at: Montreal Heart Institute and ‘‘Universite´ de
Montre´al’’, 5000 Belanger Street, Montreal, Quebec, Canada, H1T 1C8.
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1877-0657/ 2016 Published by Elsevier Masson SAS.co-morbidities including obesity, diabetes, hypertension and
dyslipidemia, all of which continue to play a role in long-term
prognosis. Therefore, poor nutrition plays a major role in the
initiation and maintenance of the atherosclerotic process, but diet
has a major role in reversing heart disease.
In this article, we discuss several contemporary topics in CV
nutrition, some of which are controversial, including recent
ﬁndings regarding the Mediterranean diet (MED) and CV risk,
the role of saturated fatty acids and red meat in CVD and
personalized nutrition for CV prevention.
2. The Mediterranean diet: recent ﬁndings
Most dietary patterns that have been studied for their
cardiometabolic properties (e.g. DASH, Mediterranean, Nordic
diets) are based on similar principles, that natural, nutrient-rich
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widely known MED has been largely investigated since its ﬁrst
description by Keys et al. [3]. Brieﬂy, this dietary pattern is rich in
fruits and vegetables, legumes and grains, with moderate
consumption of ﬁsh, low-fat dairy products, and alcohol and
relies on extra-virgin olive oil (EVOO) as its main source of dietary
fat [4]. The nutritional composition of the MED is thus rich in
monounsaturated fatty acids (MUFAs), primarily oleic acid, dietary
ﬁbers, and antioxidant compounds such as polyphenols, in
addition to a high ratio of omega-3 to omega-6 polyunsaturated
FAs. This dietary pattern is also characterized by low consumption
of highly processed foods, red meats and vegetable oils other than
EVOO, so it is poor in saturated FAs (SFAs), industrially produced
trans fats and simple sugars.
Epidemiological and accumulating clinical studies have dem-
onstrated the beneﬁts of the MED and its constituents that act in
synergy to prevent the development of CVD and its risk factors in
the primary prevention setting. For example, a recent meta-
analysis of epidemiological and prospective trials concluded that a
two-point increase in adherence to the MED, measured by the MED
score elaborated by Panagiotakos et al. [5] was associated with a
10% reduction in all-cause mortality in healthy people of all age
groups and in CV risk [6]. On a practical level, a two-point increase
in MED score requires a modest increase in consumption of
beneﬁcial foods including fruits, vegetables, legumes, grains and
ﬁsh combined with a modest decrease in detrimental foods such as
processed and unprocessed red meats. Such dietary modiﬁcations
are thus attainable and implementable at the population level. As
noted below, data regarding the beneﬁts of the MED in secondary
prevention are more limited [7,8] but are wholly consistent with
primary prevention studies.
The largely covered PREDIMED intervention trial and the
plethora of post hoc-related analyses have revealed for the ﬁrst
time in a randomized controlled trial (RCT) the CV and
cardiometabolic beneﬁts of the MED in people without overt
CVD but at high risk. The study involved 7447 Spanish participants
with type 2 diabetes mellitus (T2DM) or at least 3 traditional CV
risk factors who were randomized to receive a low-fat control diet
or 1 of 2 MEDs (supplemented with large quantities of EVOO or
mixed nuts). Adherence to a MED decreased the incidence of
stroke, myocardial infarction (MI) or CV death by 30% [9]. As well,
adherence to a MED (particularly in the increased nut-consump-
tion group) signiﬁcantly reduced the prevalence of metabolic
syndrome and diabetes in the context of an ad libitum diet [10–
12]. PREDIMED interventions positively affected other intermedi-
ate CV endpoints: they normalized levels of B-type natriuretic
peptide, oxidized LDL, and lipoprotein(a) [13]; improved plasma
antioxidant status [14]; and decreased the prevalence of hyper-
tension [15].
However, conclusions from the PREDIMED trial require
interpretation with caution [16]. In reality, all 3 groups had
similar baseline diets, which reﬂected a high degree of adherence,
on average, to the MED [9,17]. At the end of the trial, the proportion
of energy intake from total fat was only slightly lower in the low-
fat control group (37%) relative to the MED groups (41%), whereas
that from saturated fat was similar among the groups [16]. Al-
though adherence to the MED was increased in the olive oil and nut
groups, the major differences in terms of the control diet were the
higher MUFA content (from increased EVOO consumption and nut
consumption) and PUFA content (from nut consumption). Thus,
correctly speaking, PREDIMED demonstrated that consumption of
signiﬁcant quantities of EVOO or nuts in addition to a MED reduced
fatal and non-fatal CV endpoints relative to a MED alone.
Nonetheless, PREDIMED demonstrated that minor and thus
sustainable dietary modiﬁcations to already ‘‘healthy’’ habits
can beneﬁt CV health and lower event rates.Since the publication of both the GISSI-Prevenzione [7] and
Lyon Diet Heart studies [8], no additional prospective RCTs have
evaluated the impact of the MED or its constituents on the
secondary prevention of CVD. Brieﬂy, GISSI-Prevenzione demon-
strated in 11,324 Italian subjects with recent MI that supplemen-
tation with ﬁsh oil (1 g EPA + DHA) reduced the risk of CV death
relative to placebo by 17–30% after a mean follow-up of 3.5 years
[7]. In contrast, in the Lyon Diet Heart study, 423 patients with
recent acute MI were randomized to a control diet (prudent
Western diet) or a MED and followed for 45 months, on average
[8]. Similar to PREDIMED, the MED group received canola oil as a
supplement to increase dietary content of alpha-linolenic acid. The
study demonstrated that adherence to the MED reduced the
composite endpoint of cardiac death and non-fatal MI by 72%
(P = 0.0001) and risk of cardiac death alone by 65% (P = 0.01). Taken
together, the results of PREDIMED, GISSI-Prevenzione and the Lyon
Diet Heart studies demonstrate that as one moves from primary to
secondary prevention of CVD and from targeted supplementation
of a speciﬁc constituent to a holistic MED pattern, the beneﬁts of a
MED on hard clinical endpoints are even greater. Recent data from
an observational study support this view. In a substudy of the
STABILITY trial, which included over 15,000 patients with stable
coronary heart disease (CHD), adherence to a MED was associated
with reduced risk of major adverse cardiac events including CV
death, non-fatal MI and non-fatal stroke in the context of optimal
contemporary medical management [18]. In contrast, adherence to
a Western-type diet rich in reﬁned grains, carbohydrates and deep-
fried foods was not associated with poorer outcomes. As noted by
the authors, these data suggest that consumption of healthy foods
is more important than avoidance of less healthy foods for
secondary prevention of CV events [18].
3. Controversies in cardiovascular nutrition
3.1. Saturated fatty acids
In the past 2 years, much confusion has surrounded the role of
SFAs in the pathogenesis of CHD because of the publication of
meta-analyses that have suggested deleterious effects on CV health
falsely attributed to these fats over the past 40 years [19,20]. The
ﬁrst meta-analysis of Chowdhury et al. concluded that their
ﬁndings ‘‘did not yield clearly supportive evidence for current
cardiovascular guidelines that encourage high consumption of
polyunsaturated fatty acids and low consumption of saturated
fats’’ [19]. However, many experts in the ﬁeld have criticized the
authors’ methodology, notably, that one study in particular, the
Sydney Diet Heart Study [21], should not have been included in the
meta-analysis because the supplemented source of w-6 PUFAS was
a trans fat-based margarine [22]. Moreover, according to Dawc-
zynski et al., in the analyses of circulating blood fatty acid
composition, 2 studies [23,24] ﬁnding negative associations
between SFAs from dairy products (pentadecanoic acid (15:0)
and heptadecanoic acid (17:0)) and MI should not have been
included because dairy sources of SFAs do not reﬂect total SFA
intake [25]. By eliminating the 2 studies, Dawczynski et al. found a
harmful association between SFA blood levels and coronary
outcomes.
The meta-analysis by de Souza et al. also found no association
between SFA intake and CV mortality or total CHD [20]. However, a
positive trend association between SFA intake and CHD mortality
was found. The methodology of this meta-analysis is arguable.
Indeed, the study included observational studies, conducted over a
very broad time range, from 1981 to 2014, and in very
heterogeneous populations. Moreover, the studies included did
not all consider which macronutrient replaced the SFAs [26]. In one
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of fatal CHD was decreased with SFAs replaced by PUFAs
[27]. Similarly, a pooled analysis of 11 prospective cohort studies
found a 13% decrease in coronary events (hazard ratio [HR] 0.87,
95% CI 0.77–0.97) and a 26% decrease in coronary deaths (HR 0.74,
95% C 0.61–0.89) with a 5% lower energy intake from SFAs and a
concomitant higher energy intake from PUFAs [28]. A 7% increase
in coronary events (HR 1.07, 95% CI 1.01–1.14) was found for intake
of carbohydrates.
However, the meta-analysis of Mozaffarian et al., which
included 8 RCTs and no observational studies, demonstrated a
10% reduction in risk of CHD events per 5% increase in energy
intake from PUFAs, with absence of heterogeneity among studies
[29]. Also, a recently updated Cochrane systematic review of
15 RCTs addressing the same question concluded that reduced SFA
intake resulted in a 17% decrease in CV events, with the greatest
beneﬁt observed by substituting SFAs with PUFAs [30]. From these
ﬁndings, the question is whether saturated fats are harmful and
also whether in a balanced isocaloric diet, other types of fat or
macronutrients are cardioprotective. To properly address this
question, we need RCTs examining the replacement of saturated
fat by other macronutrients as part of a globally cardioprotective
diet. In fact, a recent RCT found an inverse association of SFAs
replaced by MUFAs or PUFAs with CVD [31].
Adding to the complexity of this topic, SFAs appear to be a more
heterogeneous group of FAs than was previously thought.
According to a recent case-cohort study, the association of plasma
phospholipid SFA intake and incident T2DM varied by length of the
carbon chain of the fatty acid and number of carbon atoms (odd or
even-chain) [32]. Intake of even-chain SFAs [myristic acid (14:0),
palmitic acid (16:0) and stearic acid (18:0)] was positively
associated with T2DM, with only a trend found for stearic acid
in multivariable models (HR 1.06, 95% CI 1.00–1.13) and in half the
sensitivity analyses. Conversely, intake of odd-chain SFAs [penta-
decanoic acid (15:0), heptadecanoic acid (17:0)] and longer-chain
SFAs [arachidic acid (20:0), behenic acid (22:0), tricosanoic acid
(23:0), lignoceric acid (24:0)] was inversely associated with T2DM.
However, intake of plasma phospholipid SFAs was not well
correlated with food intake. Intake of even-chain SFAs was mostly
positively associated with alcohol consumption. More studies are
needed to assess the association between SFA subgroup intake and
CV risk. In summary, we have limited high-quality data evaluating
the exact role of SFAs in the development of CVD. At this time,
intake of saturated fat overall appears to be modestly associated
with CV risk, although some SFAs may be more harmful than others
and others may be protective.
3.2. Cholesterol
According to a recent systemic review and meta-analysis,
intervention trials showed that dietary cholesterol intake increases
levels of total cholesterol, LDL-C (except for cholesterol doses
>900 mg/day) and HDL-C cholesterol and the LDL to HDL ratio
[33]. However, cohort studies show no association between
cholesterol intake and the risk of CHD and stroke.
Whether cholesterol, saturated fat or both play a role in the
development of CHD may remain unsolved. The ﬁrst plausible
explanation for the lack of convincing evidence is the complexity of
measuring the food intake of individuals or populations. In
observational studies, dietary intake is measured with food
frequency questionnaires or dietary history interview [28]. Corre-
lations between food frequency questionnaire data and diet
records, considered more accurate, rarely exceed 0.7 [34]. Second,
some nutrients may be more detrimental when eaten with other
nutrients, cholesterol being eaten simultaneously with saturated
fat, for example. In this context, food patterns may be moreappropriate in determining protective foods habits than nutrients
studied separately. Indeed, as noted previously, the MED has been
shown to protect against CVD [9]. Again, this dietary pattern is low
in animal products and therefore low in cholesterol and saturated
fat while being simultaneously high in MUFAs, primarily from olive
oil [4]. In contrast, the Western diet, which is high in saturated fat,
cholesterol, and reﬁned sugars, has greatly contributed to the
obesity epidemic and the major increase in prevalence of CVD
[35]. In other words, the complete diet may have a more important
role in health and disease than its individual constituents.
3.3. Carbohydrates
Total fat intake and types of fat have drawn much attention in
the past years, but carbohydrates seem to be more detrimental.
Carbohydrates, and especially reﬁned starches such as white rice
and major sources of added sugars, such as soft drinks, have been
linked to the global obesity epidemic [35]. Indeed, Mozaffarian
et al. observed an association between weight gain and foods rich
in carbohydrates such as potato chips, potatoes and sugar-
sweetened beverages in the US population [36]. As mentioned
previously, CHD risk increases with SFAs replaced by carbohy-
drates [28]. However, carbohydrates from whole grains appear to
decrease the risk of CHD as opposed to reﬁned starches and added
sugars [37]. This ﬁnding agrees with those from prospective cohort
studies ﬁnding an association of sugar-sweetened beverages with
CHD [38,39].
4. Red meat, processed meat and the microbiota
Although processed meat is clearly associated with all-cause
mortality [40,41], CV mortality [40] and CHD risk [42], the
association of unprocessed red meat and mortality remains
conﬂicting [40–42]. The gut microbiota, this promising but still
largely misunderstood organ, could explain in part these
discrepancies. Indeed, Koeth et al. described a link between
microbiota and synthesis of the proatherogenic compound
trimethylamine-N-oxide (TMAO) from L-carnitine and choline
present in red meats [43]. Dietary L-carnitine supplementation
in mice was associated with modiﬁcation of gut ﬂora leading to
increased production of TMAO and development of atheroscle-
rosis. This mechanism was not observed in mice treated with
antibiotics – and thus depleted in gut microbiota – which
suggests an obligatory role of the gut microbiota in TMAO
production [43]. Similarly, high plasma L-carnitine levels
predicted prevalent CHD and incident major adverse cardiac
events in humans [43]. Finally, increased TMAO level was found
independently associated with CV events at 3 years [43–
45]. Interestingly, a recent study found different gut microbiota
composition in CHD patients and healthy subjects [46]. Emoto
et al. demonstrated that gut microbiota composition could be a
diagnostic marker of CHD [47], but several unresolved issues
and contradictions remain.
For instance, unprocessed meats and other food items
associated with cardioprotective diets such as seafood, eggs, and
nuts contain L-carnitine and choline and might lead to TMAO
production, which is puzzling [43,48]. Such inconsistencies could
be explained by cardioprotective dietary patterns positively
affecting the gut microbiota composition and mediating the
production and cardiometabolic effect of TMAO. For instance,
dietary habits that positively affect gut microbiota composition
such as vegetarianism attenuated TMAO production with L-
carnitine supplementation [43]. Fig. 1 illustrates the interaction
between lifestyle factors, genetics, the intestinal microbiome and
development of CVD or its risk factors.
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time?
Dietary recommendations emitted by government and other
health agencies worldwide are meant to improve health at the
population level. Furthermore, they are necessarily based on data
from epidemiological studies and clinical trials showing that
certain foods or nutrients are beneﬁcial or deleterious, on average,
to health. However, this approach does not consider the great
interindividual variability in response to different treatments
including diet. In other words, the response to a dietary
intervention can vary considerably among individuals, with no
beneﬁt in some and substantial beneﬁt in others. No doubt, this
interindividual variability has among other factors a genetic basis
resulting in functional differences in multiple biological systems.
However, the situation is further complicated by most chronic
diseases including CVD being polygenic, or complex traits, in which
multiple genes have small but inﬂuential effects on disease
processes. Despite this fact, better understanding the causes andHUMAN BODY
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Fig. 1. Relationship between lifestyle factors, genetics, microbiome and the
development of cardiovascular disease.taking advantage of interindividual variability by personalizing
nutritional recommendations to each individual’s proﬁle could
increase the likelihood of successfully preventing and reversing
chronic diseases. Furthermore, individuals given personalized
dietary advice tend to be more compliant with recommendations
and have greater drive to change habits, at least in the initial phase
of an intervention program [49]. However, multiple interacting
systems – notably genomics, epigenomics, transcriptomics,
metabolomics, lipidomics and microbiota composition – can affect
nutrient absorption, metabolism and excretion, thus affecting
exposure to nutrients and their metabolites and affecting
individuals’ responses to nutritional interventions. Recent advan-
ces in high-throughput technologies and the sophistication of
computational algorithms are increasingly allowing researchers to
proﬁle and dissect the ﬂurry of omics data and pave the way
toward personalized medicine and nutrition.
Genetics is the highest level that can explain interindividual
variability in nutrition – referred to as nutrigenetics – whereby, for
example, the genetic susceptibility to a CV risk factor can be
mediated by dietary habits. Such gene–diet interactions were ﬁrst
identiﬁed in the apolipoprotein (APO) gene family, which codes for
apolipoproteins that play a vital role in lipid metabolism and are
thought to play a role in atherosclerosis [50]. One example is
APOA1 gene. LDL-cholesterol levels were lowered to a greater
degree with a high-PUFA diet in female carriers of the APOA1 A
allele than women who were homozygous for the GG allele
[51]. Interestingly, no gene–diet interaction was observed in men.
In an observational study, high PUFA intake was associated with
high HDL-C levels in female carriers of the APOA1 AA allele, but the
opposite was true for female GG carriers [52]. Again, no such
interactions were observed in men. These ﬁndings illustrate nicely
how the response to diet varies greatly by genetic proﬁle and sex.
Recent ﬁndings from PREDIMED have uncovered other important
gene–diet interactions. For instance, TT homozygotes for the
rs7903146 polymorphism of transcription factor 7-like 2 gene
(TCF7L2), one of the most important genetic predispositions to
T2DM [53], did not show the expected higher fasting glycemia with
high adherence to the MED relative to CC and CT carriers [54]. In
contrast, low adherence to the MED was associated with
signiﬁcantly higher fasting glycemia among TT carriers. A gene–
diet interaction has been identiﬁed for the MLXIP gene coding for
carbohydrate response element binding protein. In fact, relative to
CC carriers of allele MLXIP-rs3812316, G carriers had lower
baseline triglyceridemia and, over the course of the PREDIMED
study, signiﬁcantly greater decrease in triglycerides level, and the
incidence of MI was also reduced with high adherence to the MED
[55]. Finally, the rs4580704 single nucleotide polymorphism (SNP)
variant of the circadian locomotor output cycles protein kaput
(CLOCK) gene, which plays a role in circadian regulation of glucose
metabolism, mediated the interaction between MED and incidence
of T2DM in non-T2DM participants in PREDIMED [56]. Moreover,
presence of the rs4580704 SNP was associated with increased risk
of stroke only in T2DM participants.
Gene–diet interactions have been identiﬁed in cohorts with
pre-existing CVD. Indeed, CHD homozygotes for an allele of the
apolipoprotein C-III gene (APOC3-455C) showed reduced response
to the triglyceride-lowering effect of omega-3 PUFA supplemen-
tation [57]. In addition, CHD carriers of the rs4580704 SNP of the
CLOCK gene on a low-fat diet showed marked reduction in
inﬂammation markers and HDL to APOA1 ratio [58].
Epigenetic modiﬁcations can also account for gene–diet
interactions in what can be referred to as nutri-epigenetics.
Brieﬂy, epigenetic modiﬁcations refer to transcriptional (i.e.,
histone modiﬁcation, DNA methylation) or post-transcriptional
(i.e., microRNA, small nucleolar RNA) modiﬁcations that regulate
gene expression or protein synthesis, respectively. For example,
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structure via histone modiﬁcation can affect the access of the
transcription machinery to DNA and thus modulate gene expres-
sion. Similarly, microRNAs can bind RNA and typically interfere
with ribosomes to lower translation of RNA into proteins. All these
events can be mediated by and affect the response to diets. In fact,
foods and dietary habits that provide varying amounts of methyl
donors such as methionine, choline, betaine, folate, vitamin B12
and zinc could affect DNA methylation [59] and in turn an
individual’s response to dietary intervention. This ﬁeld is still in its
infancy, but evidence of nutri-epigenetic interactions have been
observed in C allele carriers of a microRNA target site variant
(rs13702) of the lipoprotein lipase gene that modulates triglycer-
ide levels and risk of stroke depending on level of adherence to the
MED [60].
Although existing nutrigenetic evidence is highly intriguing, the
current exploration of gene–diet interactions is only partial. In fact,
the identiﬁcation of single-gene polymorphisms probably cannot
fully explain interindividual differences in response to diets, which
results from the interaction between the many diverse nutritional
components contained in each food item and multiple biological
systems. Response to diets is presumably explained by the sum of
multiple SNPs, most of which are probably still unknown or not
fully characterized, each contributing modestly to the observed
phenotype. However, the many biological processes that can be
modulated by the known and yet to be discovered genetic
polymorphisms can be functionally evaluated by the metabolites
involved in such processes.
Indeed, untargeted metabolomics – which hereafter includes
lipidomics – enables the quantiﬁcation of chemical entities
involved in cellular processes and that can in many instances be
derived and/or affected by nutrient intake. Therefore, metabolites
can often be considered intermediate phenotypes between genetic
polymorphisms and metabolic response to nutrition and may help
in our comprehension of the determinants of an individual’s
response to diet and contribute to personalized nutrition.
Metabolomics can thus serve as a better proxy than genomics to
functionally evaluate multiple biological pathways simultaneous-
ly, proﬁle individuals’ exposure to nutrients and their metabolites,
thus globally capturing all features contributing to food response.
Metabolomics proﬁling is usually conducted with biological ﬂuids
such as plasma or urine but can also be conducted with tissue or
cells. Additionally, metabolomics improves the evaluation of
dietary habits and the assessment of compliance to interventions
better than traditionally used food frequency questionnaires and
diaries. In doing so, it also accounts for the variability in nutritional
composition between similar foods grown or produced in different
environments or submitted to different storage and processing
methodologies.
Metabolomic proﬁling has been used to detect early alterations
in phospholipid metabolism in people without T2DM who carry
the rs7903146 variant of the TCF7L2 gene [61]. This gene is
strongly associated with the development of T2DM. In contrast,
participants lacking the rs7903146 variant showed no abnormali-
ties of phospholipid metabolism in the same study. Metabolomic
proﬁling has also been successful in distinguishing metabolically
healthy from metabolically unhealthy obese people [62] and
assessing metabolic disturbances associated with heart failure
[63]. In the PREDIMED trial, urinary metabolomic proﬁles reﬂected
dietary habits and were affected by dietary interventions, so
investigators could identify which of the three arms of the trial
participants were in [64].
Another area that accounts in part for interindividual variability
in response to diets is gut microbial diversity in composition and
function. In fact, the intestinal tract is lined with a highly dynamic
microbial community that is affected by multiple and still largelymisunderstood factors ranging from host genotype, health
condition, life stage, dietary habits and lifestyles [65]. Various
microbial species will differently interact and metabolize ingested
nutrients and thus affect host exposure to their derivatives. Gut
microbiota composition can be characterized from fecal samples
but is only a non-functional proxy of the microbial composition of
the distal intestinal tract. Alternatively, by measuring circulating
metabolites, metabolomics is a more relevant proxy of gut
microbiota composition and function because some of the
measured compounds would be derived from the microbiome.
For instance, TMAO can be quantiﬁed in plasma to help identify
individuals with an unfavorable microbiota composition that
would be at increased risk of atherosclerosis and thus in whom
food items rich in choline and L-carnitine should be largely
avoided.
Ultimately, dynamic assessment of individual metabolomic
proﬁles over time and over the course of different nutritional and
lifestyle interventions could help demystify the causes of
interindividual variability to diets and tailor appropriate inter-
ventions. However, further progress is still required for such an
approach to be fully beneﬁcial to personalized nutrition. Impor-
tantly, not all entities that can be quantiﬁed by metabolomics
technologies have been characterized or mapped onto biological
pathways, so their interpretation is difﬁcult. Also, most metabo-
lomic studies have involved plasma or urine samples, which may
not be fully representative of tissue-speciﬁc functionality.
From the current state of knowledge, the soundest approach is
to group individuals by similar metabolomic proﬁles or metabo-
types. Individuals who share metabotypes may respond similarly
to diets or nutrients such as that observed with vitamin D
supplementation [66] or to red wine polyphenols in people at high
CV risk [67]. Metabotypes were also successfully identiﬁed and
used to deliver personalized recommendations to people with high
cardiometabolic risk [68]. However, in this trial, unsupervised
algorithms only needed anthropometric and traditional cardio-
metabolic markers (i.e., BMI, waist circumference, fasting glycemia
and lipemia, blood pressure) to identify clusters of similar
individuals, which questions the added value of using further
metabolomics. Similarly, one of the ﬁrst, albeit imperfect and
incomplete, examples of the use of multiple levels of data to
personalize nutritional advice was recently described [69]. In this
trial, for 800 healthy participants, baseline anthropometric data,
dietary habits and gut microbiota composition was evaluated, and
plasma glucose content was continuously monitored over 7 days.
On the basis of these parameters, a machine-learning algorithm
was able to accurately predict individual postprandial glycemic
response to standardized meals. With validation in a second
cohort, this algorithm relied on meal-related and some microbiota-
related characteristics to deliver personalized dietary recommen-
dations to minimize postprandial glycemia.
In summary, omics technologies appear attractive; however,
current knowledge is too limited for these technologies to move
out of the research domain and be fully applied to the clinical and
personalized nutrition ﬁelds. Further exploration of gene regula-
tion of protein expression and its functional impact on biological
pathways as well as integration of multiple levels of omics is
needed to capture all features of interindividual variability
[59,70,71]. Other major challenges facing this approach include
optimizing clinical study design (e.g., cohort vs. case–control
studies), dealing with varying sample sizes, data analysis,
statistical considerations including the use of many biomarkers
in small samples, and standardization of analytic techniques and
nomenclature [36] (Table 1). Furthermore, a multidisciplinary
approach is required. Current initiatives of omics proﬁling of large
numbers of individuals with varying health statuses are moving in
this direction and will, once completed, lead the ﬁeld toward more
Table 1
Personalized cardiovascular nutrition: current challenges and limitations.
Cardiovascular diseases are polygenic, complex traits
Limited number of gene variants identiﬁed
Choice of clinical study design
Optimization of data analysis techniques
Choice of sample size
Statistical considerations for multimarker studies with small sample size
Standardization of analytic techniques
Nomenclature
Requires a multidisciplinary approach
S. Lacroix et al. / Annals of Physical and Rehabilitation Medicine 60 (2017) 36–42 41effective personalized nutrition [71]. The ﬁgure illustrates the
interaction between lifestyle factors, genetics, the intestinal
microbiome and the development of CVD or its risk factors.
6. Conclusions
Large clinical studies continue to demonstrate the signiﬁcant
health beneﬁts associated with adherence to the MED in both the
primary and secondary prevention of CHD. Even among regions
surrounding the Mediterranean sea, increased adherence to the
MED provides additional beneﬁts, so even small, sustained, and
easily implementable changes to diet can have a major impact on
highly relevant clinical outcomes. Controversy remains regarding
the exact role of SFAs in the development of atherosclerosis and
vascular disease. Data must be interpreted with caution given the
extreme heterogeneity of study populations, type of study design,
interventions, and data analysis techniques, notwithstanding that
some SFAs may be more harmful than others and others may even
provide beneﬁt. What is more apparent is that in both the
developing and developed world, the driving factor behind CV risk
is excess weight, induced largely by the consumption of excessive
quantities of reﬁned carbohydrates. A multi-pronged approach
will be required to tackle this problem, with public education and
increased awareness, government policies to discourage the
production and utilization of reﬁned sugar and grain products,
and changes in the food industry, which needs to be made more
accountable for the health of the general public.
Beyond clinical outcomes, emerging data is now illustrating
how response to the MED can vary signiﬁcantly among individuals
depending on their genetic make-up and the presence or absence
of gene variants, so-called gene–diet interactions or nutrigenetics.
This and other omics technologies continue to be evaluated to
develop a robust and standardized personalized nutrition ap-
proach. Given that this approach is still in its early stages and must
overcome many challenges, it cannot be recommended for clinical
use at this time, despite commercial interests. Rather, a phenotypic
and metabotypic approach appears more useful, whereby individ-
uals with a similar metabotype can respond to an intervention in a
similar fashion. Nevertheless, the future of personalized CV
nutrition remains bright.
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